The First-Mover Advantage in Mass Torts: How Early Signal Detection Wins Cases

In mass tort litigation, timing isn't everything — but it's close.

The firms that identified Roundup lymphoma risk in 2015, PFAS contamination in 2016, or GLP-1 gastroparesis in 2023 didn't just get more cases. They got better cases, cheaper acquisition costs, and stronger positioning in MDL leadership.

The firms that waited got the scraps.

The Economics of Timing

Consider the lifecycle of a mass tort from the plaintiff firm's perspective:

Phase 1 — Signal Detection (12-24 months before MDL)

• Scientific evidence emerging but not widely known
• Few attorneys involved, minimal competition
• Case acquisition cost: $50-200 per lead
• Firms with early intelligence build inventory quietly

Phase 2 — Litigation Launch (6-12 months before MDL)

• First lawsuits filed, legal media coverage begins
• Case acquisition competition increases
• Case acquisition cost: $200-500 per lead
• MDL petition filed

Phase 3 — MDL Formation (0-12 months after)

• Major advertising campaigns launch
• TV, digital, and social media saturated with ads
• Case acquisition cost: $500-2,000+ per lead
• Plaintiff Steering Committees selected (favoring early filers)

Phase 4 — Mature Litigation (12+ months after MDL)

• Every mass tort firm is competing for the same cases
• Case acquisition cost: $2,000-5,000+ per lead
• Lead quality declines as the easy cases are taken
• Firms without early inventory struggle for MDL role

The math is stark: a firm that enters at Phase 1 pays 10-40x less per case than a firm that enters at Phase 4.

How Early Signal Detection Works

LEWS monitors 13 signal types across 12 data sources to identify emerging mass tort opportunities:

By the time attorney ads appear, the early movers have been building their practices for a year or more.

Case Study: GLP-1 Litigation

Here's how the GLP-1 timeline played out in LEWS:

2024 Q1-Q2: LEWS flagged surging FAERS adverse event reports for semaglutide. Consumer complaint signals on Reddit described gastroparesis symptoms. PubMed studies linked GLP-1 drugs to serious GI injuries. Our system classified this as a first-mover opportunity — on-market products with serious harm signals and no existing MDL.

2024 Q3-Q4: First lawsuits filed. JAMA Ophthalmology published the NAION study. Case filing activity accelerated.

2025: MDL 3094 formed for GI injuries. MDL 3163 formed for vision loss. Advertising campaigns launched nationwide.

2026: 3,546+ cases pending. Case acquisition costs have skyrocketed.

The firms that acted on LEWS-type intelligence in early 2024 are now sitting on large inventories acquired at a fraction of today's cost.

The 46 Products We're Watching

LEWS currently tracks 46 on-market products across pharmaceuticals, medical devices, and consumer chemicals. For each, we monitor:

• FDA adverse events (serious, death, hospitalization)
• Published medical research
• Consumer complaints and sentiment
• Court filings and docket activity
• Regulatory enforcement actions
• Attorney advertising patterns

Products are scored across six dimensions: causal evidence, exposed population, defendant viability, regulatory corroboration, litigation momentum, and market timing. When a product crosses our threshold, it's flagged as a first-mover opportunity.

What We've Identified

We can't share our full watchlist publicly — that's the competitive intelligence our subscribers pay for. But we can say this: several products currently on market have adverse event profiles that mirror the early stages of GLP-1 litigation.

The signals are there. The question is whether you're watching for them.